Cannabis Science Goes Live with Two National Business Radio Show Interviews Beginning Tomorrow Covering the Nation with Stu Taylor's "Equity Strategies Show"

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report that it will be featured on two broadcast radio shows beginning tomorrow with Stu Taylor and the Equity Strategies Show. Mr. Taylor will interview Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., discussing the Companys strategies with its FDA Drug approval programs, the Companys progress to date with its critical drug release programs, and future planning for subsequent drug releases through additional Federal and State government agencies.

Stu Taylor is a well renowned talk show host and currently hosts three business radio shows: Equity Strategies on the Business Talk Radio Network, Equity Strategies on the Radio America Network, and Stu Taylor on Business, aired on WBIX-AM (1060), Boston. Mr. Taylor is also a contributor to televisions Fox Business Network.

Listeners can tune into Stu Taylor and Dr. Melamedes initial discussion airing Wednesday the 23rd of September at 8:06am Eastern on WBIX 1060 AM. The show starts at 8am Eastern, covering the New England States of Maine, Vermont, New Hampshire, Massachusetts, Rhode Island, and Connecticut. You can also go to www.WBIX.com and listen to the broadcast or download the stream for future reference.

The second interview with Stu Taylor and Dr. Melamede will be aired on Saturday the 26th of September at 9pm Eastern covering 32 different cities spread across the Nation. The show will air on 32 different Radio Stations within the Business Talk Radio Network, which will be simulcast on www.BusinessTalkRadio.net for listeners to tune in over the Internet as well.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.